Literature DB >> 8699325

Partitioning of ifosfamide and its metabolites between red blood cells and plasma.

G Momerency1, K Van Cauwenberghe, M S Highley, P G Harper, A T Van Oosterom, E A De Bruijn.   

Abstract

A recently developed GC-MS analytical method for the quantitative determination of oxazaphosphorines and their metabolites in blood plasma, using stable trifluoroacetyl derivatives and electron capture negative chemical ionization detection, was applied to measure the partitioning of the antitumor drug ifosfamide and its metabolites between plasma and red blood cells for four cancer patients. The separation of a constant volume of red blood cells was performed using a special instrument, MESED, through centrifugation of blood samples. The measured compounds were ifosfamide, 2- and 3-dechloroethylifosfamide, 4-ketoifosfamide, carboxyifosfamide, ifosfamide mustard, 2-chloroethylamine and 1,3-oxazolidin-2-one. Concentration-time profiles for the metabolites in the two blood fractions and partitioning factors between erythrocytes and plasma were obtained. For ifosfamide itself, and metabolites with an intact ring system, a partitioning factor between 1 and 2 was observed for the concentration ratio between red blood cells and plasma in the patients studied. However, for the compounds with an open structure, carboxyifosfamide and ifosfamide mustard, partitioning factors higher than 3 were obtained. The active antitumor metabolite ifosfamide mustard showed a strong preference for the red blood cells in the measured patient samples. This means that erythrocytes may play an important role in the transport and the subsequent release of the active alkylating agent to the tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699325     DOI: 10.1021/js950156a

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

Review 1.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

Authors:  Dirk Schrijvers
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.